Potential of CDC25 phosphatases in cancer research and treatment: key to precision medicine

Abstract

The global burden of cancer continues to rise, underscoring the urgency of developing more effective and precisely targeted therapies. This comprehensive review explores the confluence of precision medicine and CDC25 phosphatases in the context of cancer research. Precision medicine, alternatively referred to as customized medicine, aims to customize medical interventions by taking into account the genetic, genomic, and epigenetic characteristics of individual patients. The identification of particular genetic and molecular drivers driving cancer helps both diagnostic accuracy and treatment selection. Precision medicine utilizes sophisticated technology such as genome sequencing and bioinformatics to elucidate genetic differences that underlie the proliferation of cancer cells, hence facilitating the development of customized therapeutic interventions. CDC25 phosphatases, which play a crucial role in governing the progression of the cell cycle, have garnered significant attention as potential targets for cancer treatment. The dysregulation of CDC25 is a characteristic feature observed in various types of malignancies, hence classifying them as proto-oncogenes. The proteins in question, which operate as phosphatases, play a role in the activation of Cyclin-dependent kinases (CDKs), so promoting the advancement of the cell cycle. CDC25 inhibitors demonstrate potential as therapeutic drugs for cancer treatment by specifically blocking the activity of CDKs and modulating the cell cycle in malignant cells. In brief, precision medicine presents a potentially fruitful option for augmenting cancer research, diagnosis, and treatment, with an emphasis on individualized care predicated upon patients’ genetic and molecular profiles. The review highlights the significance of CDC25 phosphatases in the advancement of cancer and identifies them as promising candidates for therapeutic intervention. This statement underscores the significance of doing thorough molecular profiling in order to uncover the complex molecular characteristics of cancer cells.

Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation

“…Nanotechnology has been shown to be a promising approach in targeting HIF in cancer therapy [ 111 , 112 , 113 , 114 , 115 ]. It can have a role in regulating oxygen content, directly inhibiting HIF-1α expression or interfering with the HIF-1α signal to control tumor cells’ malignancy and associated resistance to therapy.…”

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

“…The regulatory framework must adapt to the rapidly changing landscape of precision medicine, where treatments are increasingly tailored to specific genetic profiles . Collaboration between regulatory agencies, researchers, and industry partners is fundamental to streamline the approval process and bring innovative precision medicine approaches to patients in a timely manner. , …”

“…191 Collaboration between regulatory agencies, researchers, and industry partners is fundamental to streamline the approval process and bring innovative precision medicine approaches to patients in a timely manner. 192,193 Additionally, the responsible use of genetic information is a critical regulatory consideration. Genetic discrimination, where individuals could be discriminated against by employers or insurers based on their genetic makeup, is a potential concern.…”